The Australian medical sector is excited with the arrival of retatrutide, a novel dual GIP and GLP-1 receptor agonist showing impressive results in clinical trials for addressing obesity. This therapy https://getsocialsource.com/story7253903/retatrutide-australia-australia-a-potential-prospect-for-weight-management